Chapter 1. Research Scope

1.1. Research Objectives

1.2. Market Definition

1.3. Analysis Period

1.4. Market Size Breakdown by Segments

1.4.1. Market size breakdown, by phase

1.4.2. Market size breakdown, by therapeutic application

1.4.3. Market size breakdown, by service

1.4.4. Market size breakdown, by end user

1.4.5. Market size breakdown, by region

1.4.6. Market size breakdown, by country

1.5. Market Data Reporting Unit

1.5.1. Volume

1.5.2. Value

1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.1.1. Paid

2.1.2. Unpaid

2.1.3. P&S Intelligence database

2.2. Primary Research

2.3. Market Size Estimation

2.4. Data Triangulation

2.5. Currency Conversion Rates

2.6. Assumptions for the Study

2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Market Dynamics

5.1.1. Trends

5.1.2. Drivers

5.1.3. Restraints/challenges

5.1.4. Impact analysis of drivers/restraints

5.2. Impact of COVID-19

5.3. Porter’s Five Forces Analysis

5.3.1. Bargaining power of buyers

5.3.2. Bargaining power of suppliers

5.3.3. Threat of new entrants

5.3.4. Intensity of rivalry

5.3.5. Threat of substitutes

Chapter 6. Global Market

6.1. Overview

6.2. Market Volume, by Phase (2017–2030)

6.3. Market Revenue, by Phase (2017–2030)

6.4. Market Volume, by Therapeutic Application (2017–2030)

6.5. Market Revenue, by Therapeutic Application (2017–2030)

6.6. Market Volume, by Service (2017–2030)

6.7. Market Revenue, by Service (2017–2030)

6.8. Market Volume, by End User (2017–2030)

6.9. Market Revenue, by End User (2017–2030)

6.10. Market Volume, by Region (2017–2030)

6.11. Market Revenue, by Region (2017–2030)

Chapter 7. North America Market

7.1. Overview

7.2. Market Volume, by Phase (2017–2030)

7.3. Market Revenue, by Phase (2017–2030)

7.4. Market Volume, by Therapeutic Application (2017–2030)

7.5. Market Revenue, by Therapeutic Application (2017–2030)

7.6. Market Volume, by Service (2017–2030)

7.7. Market Revenue, by Service (2017–2030)

7.8. Market Volume, by End User (2017–2030)

7.9. Market Revenue, by End User (2017–2030)

7.10. Market Volume, by Country (2017–2030)

7.11. Market Revenue, by Country (2017–2030)

Chapter 8. Europe Market

8.1. Overview

8.2. Market Volume, by Phase (2017–2030)

8.3. Market Revenue, by Phase (2017–2030)

8.4. Market Volume, by Therapeutic Application (2017–2030)

8.5. Market Revenue, by Therapeutic Application (2017–2030)

8.6. Market Volume, by Service (2017–2030)

8.7. Market Revenue, by Service (2017–2030)

8.8. Market Volume, by End User (2017–2030)

8.9. Market Revenue, by End User (2017–2030)

8.10. Market Volume, by Country (2017–2030)

8.11. Market Revenue, by Country (2017–2030)

Chapter 9. APAC Market

9.1. Overview

9.2. Market Volume, by Phase (2017–2030)

9.3. Market Revenue, by Phase (2017–2030)

9.4. Market Volume, by Therapeutic Application (2017–2030)

9.5. Market Revenue, by Therapeutic Application (2017–2030)

9.6. Market Volume, by Service (2017–2030)

9.7. Market Revenue, by Service (2017–2030)

9.8. Market Volume, by End User (2017–2030)

9.9. Market Revenue, by End User (2017–2030)

9.10. Market Volume, by Country (2017–2030)

9.11. Market Revenue, by Country (2017–2030)

Chapter 10. LATAM Market

10.1. Overview

10.2. Market Volume, by Phase (2017–2030)

10.3. Market Revenue, by Phase (2017–2030)

10.4. Market Volume, by Therapeutic Application (2017–2030)

10.5. Market Revenue, by Therapeutic Application (2017–2030)

10.6. Market Volume, by Service (2017–2030)

10.7. Market Revenue, by Service (2017–2030)

10.8. Market Volume, by End User (2017–2030)

10.9. Market Revenue, by End User (2017–2030)

10.10. Market Volume, by Country (2017–2030)

10.11. Market Revenue, by Country (2017–2030)

Chapter 11. MEA Market

11.1. Overview

11.2. Market Volume, by Phase (2017–2030)

11.3. Market Revenue, by Phase (2017–2030)

11.4. Market Volume, by Therapeutic Application (2017–2030)

11.5. Market Revenue, by Therapeutic Application (2017–2030)

11.6. Market Volume, by Service (2017–2030)

11.7. Market Revenue, by Service (2017–2030)

11.8. Market Volume, by End User (2017–2030)

11.9. Market Revenue, by End User (2017–2030)

11.10. Market Volume, by Country (2017–2030)

11.11. Market Revenue, by Country (2017–2030)

Chapter 12. U.S. Market

12.1. Overview

12.2. Market Volume, by Phase (2017–2030)

12.3. Market Revenue, by Phase (2017–2030)

12.4. Market Volume, by Therapeutic Application (2017–2030)

12.5. Market Revenue, by Therapeutic Application (2017–2030)

12.6. Market Volume, by Service (2017–2030)

12.7. Market Revenue, by Service (2017–2030)

12.8. Market Volume, by End User (2017–2030)

12.9. Market Revenue, by End User (2017–2030)

Chapter 13. Canada Market

13.1. Overview

13.2. Market Volume, by Phase (2017–2030)

13.3. Market Revenue, by Phase (2017–2030)

13.4. Market Volume, by Therapeutic Application (2017–2030)

13.5. Market Revenue, by Therapeutic Application (2017–2030)

13.6. Market Volume, by Service (2017–2030)

13.7. Market Revenue, by Service (2017–2030)

13.8. Market Volume, by End User (2017–2030)

13.9. Market Revenue, by End User (2017–2030)

Chapter 14. Germany Market

14.1. Overview

14.2. Market Volume, by Phase (2017–2030)

14.3. Market Revenue, by Phase (2017–2030)

14.4. Market Volume, by Therapeutic Application (2017–2030)

14.5. Market Revenue, by Therapeutic Application (2017–2030)

14.6. Market Volume, by Service (2017–2030)

14.7. Market Revenue, by Service (2017–2030)

14.8. Market Volume, by End User (2017–2030)

14.9. Market Revenue, by End User (2017–2030)

Chapter 15. France Market

15.1. Overview

15.2. Market Volume, by Phase (2017–2030)

15.3. Market Revenue, by Phase (2017–2030)

15.4. Market Volume, by Therapeutic Application (2017–2030)

15.5. Market Revenue, by Therapeutic Application (2017–2030)

15.6. Market Volume, by Service (2017–2030)

15.7. Market Revenue, by Service (2017–2030)

15.8. Market Volume, by End User (2017–2030)

15.9. Market Revenue, by End User (2017–2030)

Chapter 16. U.K. Market

16.1. Overview

16.2. Market Volume, by Phase (2017–2030)

16.3. Market Revenue, by Phase (2017–2030)

16.4. Market Volume, by Therapeutic Application (2017–2030)

16.5. Market Revenue, by Therapeutic Application (2017–2030)

16.6. Market Volume, by Service (2017–2030)

16.7. Market Revenue, by Service (2017–2030)

16.8. Market Volume, by End User (2017–2030)

16.9. Market Revenue, by End User (2017–2030)

Chapter 17. Italy Market

17.1. Overview

17.2. Market Volume, by Phase (2017–2030)

17.3. Market Revenue, by Phase (2017–2030)

17.4. Market Volume, by Therapeutic Application (2017–2030)

17.5. Market Revenue, by Therapeutic Application (2017–2030)

17.6. Market Volume, by Service (2017–2030)

17.7. Market Revenue, by Service (2017–2030)

17.8. Market Volume, by End User (2017–2030)

17.9. Market Revenue, by End User (2017–2030)

Chapter 18. Spain Market

18.1. Overview

18.2. Market Volume, by Phase (2017–2030)

18.3. Market Revenue, by Phase (2017–2030)

18.4. Market Volume, by Therapeutic Application (2017–2030)

18.5. Market Revenue, by Therapeutic Application (2017–2030)

18.6. Market Volume, by Service (2017–2030)

18.7. Market Revenue, by Service (2017–2030)

18.8. Market Volume, by End User (2017–2030)

18.9. Market Revenue, by End User (2017–2030)

Chapter 19. Japan Market

19.1. Overview

19.2. Market Volume, by Phase (2017–2030)

19.3. Market Revenue, by Phase (2017–2030)

19.4. Market Volume, by Therapeutic Application (2017–2030)

19.5. Market Revenue, by Therapeutic Application (2017–2030)

19.6. Market Volume, by Service (2017–2030)

19.7. Market Revenue, by Service (2017–2030)

19.8. Market Volume, by End User (2017–2030)

19.9. Market Revenue, by End User (2017–2030)

Chapter 20. China Market

20.1. Overview

20.2. Market Volume, by Phase (2017–2030)

20.3. Market Revenue, by Phase (2017–2030)

20.4. Market Volume, by Therapeutic Application (2017–2030)

20.5. Market Revenue, by Therapeutic Application (2017–2030)

20.6. Market Volume, by Service (2017–2030)

20.7. Market Revenue, by Service (2017–2030)

20.8. Market Volume, by End User (2017–2030)

20.9. Market Revenue, by End User (2017–2030)

Chapter 21. India Market

21.1. Overview

21.2. Market Volume, by Phase (2017–2030)

21.3. Market Revenue, by Phase (2017–2030)

21.4. Market Volume, by Therapeutic Application (2017–2030)

21.5. Market Revenue, by Therapeutic Application (2017–2030)

21.6. Market Volume, by Service (2017–2030)

21.7. Market Revenue, by Service (2017–2030)

21.8. Market Volume, by End User (2017–2030)

21.9. Market Revenue, by End User (2017–2030)

Chapter 22. Australia Market

22.1. Overview

22.2. Market Volume, by Phase (2017–2030)

22.3. Market Revenue, by Phase (2017–2030)

22.4. Market Volume, by Therapeutic Application (2017–2030)

22.5. Market Revenue, by Therapeutic Application (2017–2030)

22.6. Market Volume, by Service (2017–2030)

22.7. Market Revenue, by Service (2017–2030)

22.8. Market Volume, by End User (2017–2030)

22.9. Market Revenue, by End User (2017–2030)

Chapter 23. South Korea Market

23.1. Overview

23.2. Market Volume, by Phase (2017–2030)

23.3. Market Revenue, by Phase (2017–2030)

23.4. Market Volume, by Therapeutic Application (2017–2030)

23.5. Market Revenue, by Therapeutic Application (2017–2030)

23.6. Market Volume, by Service (2017–2030)

23.7. Market Revenue, by Service (2017–2030)

23.8. Market Volume, by End User (2017–2030)

23.9. Market Revenue, by End User (2017–2030)

Chapter 24. Brazil Market

24.1. Overview

24.2. Market Volume, by Phase (2017–2030)

24.3. Market Revenue, by Phase (2017–2030)

24.4. Market Volume, by Therapeutic Application (2017–2030)

24.5. Market Revenue, by Therapeutic Application (2017–2030)

24.6. Market Volume, by Service (2017–2030)

24.7. Market Revenue, by Service (2017–2030)

24.8. Market Volume, by End User (2017–2030)

24.9. Market Revenue, by End User (2017–2030)

Chapter 25. Mexico Market

25.1. Overview

25.2. Market Volume, by Phase (2017–2030)

25.3. Market Revenue, by Phase (2017–2030)

25.4. Market Volume, by Therapeutic Application (2017–2030)

25.5. Market Revenue, by Therapeutic Application (2017–2030)

25.6. Market Volume, by Service (2017–2030)

25.7. Market Revenue, by Service (2017–2030)

25.8. Market Volume, by End User (2017–2030)

25.9. Market Revenue, by End User (2017–2030)

Chapter 26. Saudi Arabia Market

26.1. Overview

26.2. Market Volume, by Phase (2017–2030)

26.3. Market Revenue, by Phase (2017–2030)

26.4. Market Volume, by Therapeutic Application (2017–2030)

26.5. Market Revenue, by Therapeutic Application (2017–2030)

26.6. Market Volume, by Service (2017–2030)

26.7. Market Revenue, by Service (2017–2030)

26.8. Market Volume, by End User (2017–2030)

26.9. Market Revenue, by End User (2017–2030)

Chapter 27. South Africa Market

27.1. Overview

27.2. Market Volume, by Phase (2017–2030)

27.3. Market Revenue, by Phase (2017–2030)

27.4. Market Volume, by Therapeutic Application (2017–2030)

27.5. Market Revenue, by Therapeutic Application (2017–2030)

27.6. Market Volume, by Service (2017–2030)

27.7. Market Revenue, by Service (2017–2030)

27.8. Market Volume, by End User (2017–2030)

27.9. Market Revenue, by End User (2017–2030)

Chapter 28. U.A.E. Market

28.1. Overview

28.2. Market Volume, by Phase (2017–2030)

28.3. Market Revenue, by Phase (2017–2030)

28.4. Market Volume, by Therapeutic Application (2017–2030)

28.5. Market Revenue, by Therapeutic Application (2017–2030)

28.6. Market Volume, by Service (2017–2030)

28.7. Market Revenue, by Service (2017–2030)

28.8. Market Volume, by End User (2017–2030)

28.9. Market Revenue, by End User (2017–2030)

Chapter 29. Competitive Landscape

29.1. List of Market Players and their Offerings

29.2. Competitive Benchmarking of Key Players

29.3. Product Benchmarking of Key Players

29.4. Recent Strategic Developments

Chapter 30. Company Profiles

30.1. Thermo Fisher Scientific Inc.

30.1.1. Business overview

30.1.2. Product and service offerings

30.1.3. Key financial summary

30.2. Marken

30.2.1. Business overview

30.2.2. Product and service offerings

30.2.3. Key financial summary

30.3. Catalent Inc.

30.3.1. Business overview

30.3.2. Product and service offerings

30.3.3. Key financial summary

30.4. Parexel International

30.4.1. Business overview

30.4.2. Product and service offerings

30.4.3. Key financial summary

30.5. Almac Group Limited

30.5.1. Business overview

30.5.2. Product and service offerings

30.5.3. Key financial summary

30.6. Biocair International Limited

30.6.1. Business overview

30.6.2. Product and service offerings

30.6.3. Key financial summary

30.7. Sharp Services LLC

30.7.1. Business overview

30.7.2. Product and service offerings

30.7.3. Key financial summary

30.8. Movianto International BV

30.8.1. Business overview

30.8.2. Product and service offerings

30.8.3. Key financial summary

30.9. PCI Pharma Services

30.9.1. Business overview

30.9.2. Product and service offerings

30.9.3. Key financial summary

30.10. Eurofins Scientific

30.10.1. Business overview

30.10.2. Product and service offerings

30.10.3. Key financial summary

Chapter 31. Appendix

31.1. Abbreviations

31.2. Sources and References

31.3. Related Reports

※参考情報 臨床試験用品とは、医療研究や製品開発において、新しい治療法や薬剤の効果を評価するために使用されるさまざまな器具や素材を指します。これらの製品は、ヒトを対象とした試験に必要不可欠であり、医療の進歩や公共の健康を促進するための重要な役割を果たしています。 臨床試験用品には、主に以下のような種類があります。まず、薬剤関連の用品です。これには新薬、治療のための治療薬、プラセボ（偽薬）などが含まれます。これらは、投与方法や用量、効果を検証するために使用されます。 次に、診断機器や測定器具が挙げられます。これには血圧計、心電図、血液検査のための試薬などが含まれ、患者の健康状態や病状を把握するために必要です。また、簡易診断試薬や画期的なイメージング技術を利用した機器も、臨床試験において重要です。 さらに、参加者からデータを収集するためのアンケートやモニタリング機器も臨床試験用品に含まれます。これにより、患者の反応や副作用を詳細に把握することができ、臨床データの信頼性を高めることが可能です。 これらの用品は、単独で使われるだけでなく、時には複数の品目が組み合わさって試験が行われます。臨床試験のデザインによっては、これらの試験用品の使い方も多様化し、試験の目的に応じた特定の基準や規制が設けられることもあります。 臨床試験用品の用途は多岐にわたります。新薬の安全性、有効性を評価するための試験、病気の進行状況や予後を分析するための研究、医療機器の操作性や効果を確認する試験など、これらの用途が広がっています。そして、これらの試験を通じて集められたデータは、医薬品や医療機器の承認に必要な証拠として用いられます。 また、臨床試験用品には特定の関連技術が関連しています。例えば、デジタルヘルス技術が進化する現代においては、ウェアラブルデバイスが臨床試験におけるデータ収集方法として注目されています。これらのデバイスは、患者の活動量やバイタルサインをリアルタイムでモニタリングでき、従来の方法では得られなかったデータを取得することが可能となります。 さらに、データマネジメント技術も重要です。臨床試験では大量のデータが生成されるため、適切に分析・管理するためのソフトウェアやプラットフォームが欠かせません。これにより、データの一貫性や正確性が確保され、解析効率も向上します。 最後に、臨床試験用品は製品開発の過程で厳格な規制やガイドラインに従う必要があります。医療機関や製薬会社は、臨床試験の計画段階から承認、実施、報告までの過程で、安全性や倫理に関する基準を遵守しなければなりません。これにより、治療法や医療機器の安全性と有効性が確保され、患者に提供される医療が信頼できるものとなります。 このように、臨床試験用品は医療の発展と革新に大きく寄与しており、これからも重要な役割を果たし続けることでしょう。新たな治療法の発見、病気に対する理解の深化、そして患者の健康改善に向けた様々な試みを支える存在であります。